Breaking Finance News

Zacks Investment Research downgraded Applied Genetic Technologies Corp (NASDAQ:AGTC) to Hold in a report released today.

Zacks Investment Research has downgraded Applied Genetic Technologies Corp (NASDAQ:AGTC) to Hold in a report released on Wednesday October 12, 2016.

Previously on Tuesday October 11, 2016, Zacks Investment Research reported on Applied Genetic Technologies Corp (NASDAQ:AGTC) increased the target price from $0.00 to $11.00. At the time, this indicated a possible upside of 0.18%.

Yesterday Applied Genetic Technologies Corp (NASDAQ:AGTC) traded -2.60% lower at $9.35. The company’s 50-day moving average is $10.99 and its 200-day moving average is $14.32. The last closing price is down -34.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 102,887 shares of AGTC traded hands, down from an average trading volume of 188,320

Recent Performance Chart

Applied Genetic Technologies Corp (NASDAQ:AGTC)

Applied Genetic Technologies Corp has 52 week low of $8.50 and a 52 week high of $21.43 and has a market capitalization of $0.

Also covering Applied Genetic Technologies Corp's price target, a total of 5 brokerages have released a research note on Applied Genetic Technologies Corp. The 12-month price target is $31.20 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 equity analysts rating the company a hold, zero brokerages rating the stock a underperform, and finally zero analysts rating the company a sell.

General Company Details For Applied Genetic Technologies Corp (NASDAQ:AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.